CARsgen Therapeutics Holdings Ltd Ordinary Shares 02171
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 347.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People’s Republic of China and the United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 477
- Website
- https://www.carsgen.com
Comparables
Valuation
|
Metric
|
02171
|
ZURA
|
02256
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 321.46 |
Price/Book Value | 1.56 | 1.66 | 0.97 |
Price/Sales | 347.20 | — | 4.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02171
|
ZURA
|
02256
|
|---|---|---|---|
Quick Ratio | 9.12 | 12.50 | 21.59 |
Current Ratio | 9.47 | 12.57 | 21.75 |
Interest Coverage | −159.86 | — | −10.45 |
Quick Ratio
02171
ZURA
02256
Profitability
|
Metric
|
02171
|
ZURA
|
02256
|
|---|---|---|---|
Return on Assets (Normalized) | −29.55% | −20.26% | 0.63% |
Return on Equity (Normalized) | −39.55% | −29.67% | 0.70% |
Return on Invested Capital (Normalized) | −38.18% | −30.68% | −3.17% |
Return on Assets
02171
ZURA
02256
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mdlxvwcnh | Jctz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qwpbpjsv | Fcvzh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ldshpcrpv | Jdtkd | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cqtjpjdt | Hmqkph | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Pxtfgtwbb | Hqvxf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Tryhhqc | Vkz | $28.1 Bil | |||
| Moderna Inc
MRNA
| Dvmxbhfh | Rzvx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bgwdcvbh | Xpsl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qrcllff | Gktxw | $13.4 Bil | |||
| Incyte Corp
INCY
| Wntvdlq | Gqpwmq | $12.7 Bil |
United States